Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omiganan topical gel in mild to moderate atopic dermatitis
NL-OMON42598Phase 2Active, not recruiting
- Sponsor
- Biofrontera
- Start
- May 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omiganan in atopic dermatitis (AD) (3 arms), sponsored by Biofrontera. Primary endpoints: Local biopsy biomarkers, Skin lesion microbiome and 2 more. Started May 2015; status: active, not recruiting.
02
Drugs
omiganan
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON42598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42598.